StockNews.AI
FHTX
StockNews.AI
14 hrs

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit

1. FHTX to present Selective ARID1B progress at TPD Summit on October 29. 2. Investor event on Selective ARID1B, CBP, and EP300 on October 30. 3. Potential new drug class for endometrial, gastric, and bladder cancers highlighted. 4. Programs progressing toward IND enabling studies, reflecting therapeutic expansion potential. 5. FHTX's Gene Traffic Control platform aids target identification in chromatin regulation.

7m saved
Insight
Article

FAQ

Why Bullish?

FHTX's presentation of significant progress in drug development may attract investor interest, akin to how other biotech firms saw stock increases following positive trial news.

How important is it?

The focus on FHTX's drugs for unmet needs signals market potential, influencing investor confidence.

Why Short Term?

Upcoming events can lead to immediate stock price movements, as seen in similar biotech announcements.

Related Companies

AMGNREGNBIIB
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT October 16, 2025 07:00 ET  | Source: Foghorn Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced key development updates for its Selective ARID1B degrader program which will be presented as part of a Keynote Plenary session at the 8th Annual TPD and Induced Proximity Summit being held October 27-30, 2025, in Boston, MA. The day after the presentation, Foghorn will host a virtual investor event to review pipeline updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs. “We are excited to present significant progress for our Selective ARID1B degrader at this year’s TPD and Induced Proximity Summit. These findings highlight the potential of our Selective ARID1B degrader program to become a new class of drugs for patients with endometrial, gastric, and bladder cancers with high unmet needs,” said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. “Additionally, at our virtual investor event, we will share the continued momentum for our Selective CBP and Selective EP300 degrader programs, which are steadily progressing toward Investigational New Drug (IND) enabling studies. These collective developments reflect the potential of our protein degrader capabilities to expand therapeutic possibilities in areas with limited treatment innovation.” Presentation DetailsTitle: Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory ProteinsSession: Closing Keynote Plenary SessionDate/Time: Wednesday, October 29, 3:45 p.m. EDTPresenter: Steven Bellon, Chief Scientific Officer of Foghorn Therapeutics Foghorn Hosted Virtual Investor Event InformationTitle: Pipeline Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader ProgramsDate/Time: Thursday, October 30, 2025 at 12 p.m. EDTRegistration Link: Register here The presentation will be accessible under the Science section of the Company’s website after the conference. The live webcast will also be available under the Events & Presentations section of Foghorn’s website. A replay of the event and presentation will be available immediately following the event. About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn. Forward-Looking Statements This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, pre-clinical programs, including its Selective ARID1B degrader program and Selective CBP and Selective EP300 degrader programs, the Company’s other product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Contact: Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)khellsvik@foghorntx.com

Related News